Zhang Hang, Zhang Yingying, Zhu Yingying, Dong Tian, Liu Zheng
Department of Hematology, Institute of Hematology, West China Hospital of Sichuan University, Chengdu, China.
Department of Neurology, West China Hospital of Sichuan University, Chengdu, China.
Front Oncol. 2024 Jul 11;14:1387345. doi: 10.3389/fonc.2024.1387345. eCollection 2024.
Lung cancer remains the leading cause of mortality worldwide. Non-small cell lung cancer (NSCLC) is the most common subtype of lung cancer with a generally poor prognosis. In recent years, advances in targeted therapy and sequencing technology have brought significant improvement in the therapeutic outcomes of patients with advanced NSCLC. Targeted inhibitors directed against specific mutated or rearranged oncogenes, such as epidermal growth factor receptor (), anaplastic lymphoma kinase (), and receptor tyrosine kinase ROS proto-oncogene 1() among others, exhibit promising anti-tumor activity. Unfortunately, some patients develop acquired resistance and disease progression soon after initial remission. Despite the continuous development of new drugs and strategies to overcome drug resistance, it is still a major challenge in the treatment of NSCLC. The landscape of targeted therapy for NSCLC is evolving rapidly in response to the pace of scientific research. This study aimed to provide a comprehensive review of tumor target antigens and agents related to targeted therapy in NSCLC.
肺癌仍然是全球范围内主要的死亡原因。非小细胞肺癌（NSCLC）是肺癌最常见的亚型，总体预后通常较差。近年来，靶向治疗和测序技术的进展显著改善了晚期NSCLC患者的治疗效果。针对特定突变或重排癌基因的靶向抑制剂，如表皮生长因子受体（）、间变性淋巴瘤激酶（）和受体酪氨酸激酶ROS原癌基因1（）等，显示出有前景的抗肿瘤活性。不幸的是，一些患者在初始缓解后不久就出现获得性耐药和疾病进展。尽管不断开发新药物和克服耐药性的策略，但这仍然是NSCLC治疗中的一项重大挑战。NSCLC靶向治疗的格局正随着科学研究的步伐迅速演变。本研究旨在全面综述与NSCLC靶向治疗相关的肿瘤靶抗原和药物。
